Decision Granting Joint Motion to Terminate | Jul 31, 2019 | PAPER | BOARD |
Joint Request to Treat Settlement and License Agreement as Business Confidential | Jul 30, 2019 | PAPER | PATENT OWNER |
Joint Motion to Terminate Case No. IPR2018-00943 | Jul 30, 2019 | PAPER | PATENT OWNER |
Exhibit 2058 [Confidential] | Jul 30, 2019 | EXHIBIT | PATENT OWNER |
Order Oral Hearing | Jul 9, 2019 | PAPER | BOARD |
Petitioner's Request for Oral Argument | Jul 8, 2019 | PAPER | PETITIONER |
Patent Owner's Request for Oral Argument | Jul 8, 2019 | PAPER | PATENT OWNER |
Exhibit 2057 | Jun 21, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Sur-Reply | Jun 21, 2019 | PAPER | PATENT OWNER |
Patent Owner's Current List of Exhibits | Jun 21, 2019 | PAPER | PATENT OWNER |
Patent Owner¿¿¿s Notice Of Deposition Of Sara K. Quinney, Pharm.D., Ph.D. | May 20, 2019 | PAPER | PATENT OWNER |
Joint Stipulation to Revise Scheduling Order | May 20, 2019 | PAPER | PATENT OWNER |
Order Conduct of the Proceeding | May 14, 2019 | PAPER | BOARD |
Petitioner's Reply to Patent Owner's Response | May 7, 2019 | PAPER | PETITIONER |
Declaration of Sara K. Quinney, Pharm.D., Ph.D. | May 7, 2019 | EXHIBIT | PETITIONER |
Bertoletti et al., Effect of liver cirrhosis on the systemic availability of naltrexone in humans | May 7, 2019 | EXHIBIT | PETITIONER |
Physician's Desk Reference, 2663, 3052 3053 (55th ed. 2001) | May 7, 2019 | EXHIBIT | PETITIONER |
Michael R. Franklin, PhD, Drug Absorption, Distribution, Metabolism, and Excretion, Ch.54 The Science and Practice of Pharmacy | May 7, 2019 | EXHIBIT | PETITIONER |
Supplemental Declaration of Kinam Park, Ph.D. | May 7, 2019 | EXHIBIT | PETITIONER |
Curriculum Vita of Sara Kay Quinney | May 7, 2019 | EXHIBIT | PETITIONER |
Steven B. Johnson, PharmD, Bioavailability and Bioequivalence Testing, Ch.18 Remington 349-359 (22nd ed. 2013) | May 7, 2019 | EXHIBIT | PETITIONER |
Barbara J. Mason, Ph.D. et al., A Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Acamprosate and Naltrexone | May 7, 2019 | EXHIBIT | PETITIONER |
Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, Guidance for Industry | May 7, 2019 | EXHIBIT | PETITIONER |
Susan N. Hunt, Pharm.D. et al., Effect of smoking on theophylline disposition | May 7, 2019 | EXHIBIT | PETITIONER |
K.C. Yeh and K.C. Kwan, A Comparison of Numerical Integrating Algorithms by Trapezoidal, Lagrange, and Spline Approximation | May 7, 2019 | EXHIBIT | PETITIONER |
M.J. Gardner et al., EFFECTS OF TOBACCO SMOKING AND ORAL CONTRACEPTIVE USE ON THEOPHYLLINE DISPOSITION | May 7, 2019 | EXHIBIT | PETITIONER |
John G. Wagner & James W. Ayres, J. of Pharmacokinetics and Biopharmaceutics | May 7, 2019 | EXHIBIT | PETITIONER |
Krishna et al., Increased Intracellular Drug Accumulation and Complete Chemosensitization Achieved in Multidrug-Resistant Solid Tumors by Co-Administering Valspodar (PSC 833) With Sterically Stabilized Liposomal Doxorubicin | May 7, 2019 | EXHIBIT | PETITIONER |
Sara Rae Hamilton et al., Pharmacokinetics and Pharmacodynamics of Hyaluronan Infused into Healthy Human Volunteers | May 7, 2019 | EXHIBIT | PETITIONER |
Nikolaj Kunoe et al., Injectable and Implantable sustained release naltrexone in the treatment of opioid addiction | May 7, 2019 | EXHIBIT | PETITIONER |
Joi L. Dunbar et al., Single- and Multiple-Dose Pharmacokinetics of Long-acting Injectable Naltrexone | May 7, 2019 | EXHIBIT | PETITIONER |
Malcom Rowland and Thomas N. Tozer, Clinical Pharmacokinetics Concepts and Applications (3rd ed. 1995) | May 7, 2019 | EXHIBIT | PETITIONER |
Fotherby et al., A Preliminary Pharmacological Trial of the Monthly Injectable Contraceptive Cycloprovera | May 7, 2019 | EXHIBIT | PETITIONER |
Galinsky et al., Probenecid Enhances Central Nervous System Uptake Of 2',3' ¿¿¿ Dideoxyinosine by Inhibiting Cerebrospinal Fluid Efflux | May 7, 2019 | EXHIBIT | PETITIONER |
Zhiling Yu and Francis L. S., An Evaluation of Numerical Integration Algorithms for the Estimation of The AUC in Pharmacokinetics Studies | May 7, 2019 | EXHIBIT | PETITIONER |
C. Ediss and Y.K. Tam, An Interactive Computer Program for Determining Areas Bounded by Drug Concentration Curves Using Lagrange Interpolation | May 7, 2019 | EXHIBIT | PETITIONER |
Goonoo et al., Naltrexone: A review of existing sustained drug delivery systems and emerging nano-based systems | May 7, 2019 | EXHIBIT | PETITIONER |
Milo Gibaldi and Donald Perrier, Pharmacokinetics, 1 Drugs and Pharmaceutical Sciences (2d ed. rev. expanded 2007) | May 7, 2019 | EXHIBIT | PETITIONER |
Kogan et al., Estimation of the Systemic Availability and Other Pharmacokinetic Parameters of Naltrexone in Man After Acute and Chronic Oral Administration | May 7, 2019 | EXHIBIT | PETITIONER |
Phoenix WinNonlin(R) User Guide, Phoenix WinNonlin 8.1, Certara (2018) | May 7, 2019 | EXHIBIT | PETITIONER |
Fotherby et al., Pharmacokinetic Study of Different Doses of Depo Provera | May 7, 2019 | EXHIBIT | PETITIONER |
Yuen et al., Comparative Bioavailability Study of a Generic Naltrexone Tablet Preparation | May 7, 2019 | EXHIBIT | PETITIONER |
Malcolm Rowland and Thomas N. Tozer, Clinical Pharmacokinetics and Pharmacodynamics Concepts and Applications (4th ed.2011) | May 7, 2019 | EXHIBIT | PETITIONER |
Petitioner's Updated Mandatory Notices | Mar 25, 2019 | PAPER | PETITIONER |
Petitioner's Updated Mandatory Notice | Mar 1, 2019 | PAPER | PETITIONER |
Patent Owner¿¿¿s Response to Petition for Inter Partes Review of U.S. Patent No. 7,919,499 | Feb 7, 2019 | PAPER | PATENT OWNER |
Exhibit 2023 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2024 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2025 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2026 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2028 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2030 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2031 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2032 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2033 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2034 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2035 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2037 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2038 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2039 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2040 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2041 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2042 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2043 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2045 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2046 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2048 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2049 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2051 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2052 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2053 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2054 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Exhibit 2056 | Feb 7, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Current List of Exhibits | Feb 7, 2019 | PAPER | PATENT OWNER |
Order - 37 C.F.R. 42.10 | Jan 18, 2019 | PAPER | BOARD |
Patent Owner's Updated Mandatory Notices | Jan 17, 2019 | PAPER | PATENT OWNER |
Patent Owner's Motion for Pro Hac Vice Admission of Joseph M. O'Malley, Jr. | Jan 17, 2019 | PAPER | PATENT OWNER |
Exhibit 2022 | Jan 17, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Notice of Deposition of Kinam Park Ph.D. | Jan 8, 2019 | PAPER | PATENT OWNER |
Scheduling Order | Nov 7, 2018 | PAPER | BOARD |
Trial Instituted Document | Nov 7, 2018 | PAPER | BOARD |
Exhibit 2004 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2011 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2015 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Patent Owner's Preliminary Response to Petition for Inter Partes Review of U.S. Patent No. 7,919,499 | Aug 9, 2018 | PAPER | PATENT OWNER |
Exhibit 2001 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2002 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2003 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2005 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2006 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2007 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2008 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2009 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2010 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2012 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2013 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2014 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2016 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2017 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2018 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2019 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2020 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Exhibit 2021 | Aug 9, 2018 | EXHIBIT | PATENT OWNER |
Patent Owner's Power of Attorney | May 11, 2018 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | May 11, 2018 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | May 9, 2018 | PAPER | BOARD |
U.S. Patent No. 7,919,499 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Serial Number 11/083,167, Amendment and Response, Apr. 5, 2010 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Serial Number 11/083,167, Final Rejection, July 20, 2010 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Serial Number 11/083,167, Notice of Allowance, Dec. 1, 2010 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Patent No. 7,157,102 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Patent No. 6,264,987 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Serial Number 11/083,167, Office Action, May 5, 2009 | Apr 20, 2018 | EXHIBIT | PETITIONER |
Serial No. 11/083,167, Declaration Under 37 C.F.R. 1.132 of Elliot Ehrich (undated) | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Serial Number 11/083,167, Amendment and Response, Oct. 5, 2009 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Serial Number 11/083,167, Office Action, Jan. 6, 2010 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Serial Number 11/083,167, Amendment After Final, Oct. 20, 2010 | Apr 20, 2018 | EXHIBIT | PETITIONER |
C.N. Chiang et al., Clinical Evaluation of A Naltrexone Sustained Release Preparation | Apr 20, 2018 | EXHIBIT | PETITIONER |
T.N. Alim, et al., Tolerability Study of A Depot Form of Naltrexone Substance Abusers | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Patent No. 6,306,425 | Apr 20, 2018 | EXHIBIT | PETITIONER |
S.J. Heishman et al., Safety And Pharmacokinetics of a New Formulation of Depot Naltrexone | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Patent and Trademark Office, 1265(2) Official Gazette of the United States Patent and Trademark Office | Apr 20, 2018 | EXHIBIT | PETITIONER |
Stewart B. Leavitt, PhD, ed., Evidence for the Efficacy of Naltrexone in the Treatment of Alcohol Dependence (Alcoholism) | Apr 20, 2018 | EXHIBIT | PETITIONER |
Chiang et al., Kinetics of a naltrexone sustained-release preparation, 36(5) | Apr 20, 2018 | EXHIBIT | PETITIONER |
Reuning et al., Pharmacokinetic Quantitation of Naltrexone Release From Several Sustained-Release Delivery Systems | Apr 20, 2018 | EXHIBIT | PETITIONER |
Appeal Brief, Application No. 13/871,534, Oct. 19, 2015 | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Provisional Application No. 60/564,542 | Apr 20, 2018 | EXHIBIT | PETITIONER |
Manit Srisurapanont & Ngamwong Jarusuraisin | Apr 20, 2018 | EXHIBIT | PETITIONER |
Bouza Carmen et al., Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review, | Apr 20, 2018 | EXHIBIT | PETITIONER |
Synopsis, Naltrexone HC1, ALZA Corporation | Apr 20, 2018 | EXHIBIT | PETITIONER |
In hwan Baek et al., Evaluation of the Bioequivalence of Two Brands of Naltrexone 50 mg Tablet in Healthy Volunteers | Apr 20, 2018 | EXHIBIT | PETITIONER |
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations | Apr 20, 2018 | EXHIBIT | PETITIONER |
ReVia, Physicians Desk Reference 936 938 (53rd ed. 1999) | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Patent No. 4,882,335 | Apr 20, 2018 | EXHIBIT | PETITIONER |
J.S. Hopkins et al., Naltrexone and Acamprosate Meta Anaylsis of Two Medical Treatments for Alcoholism | Apr 20, 2018 | EXHIBIT | PETITIONER |
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations | Apr 20, 2018 | EXHIBIT | PETITIONER |
Bioequivalence, Center for Drug Evaluation and Research, Application Number | Apr 20, 2018 | EXHIBIT | PETITIONER |
TREXAN, Physicians Desk Reference 936 938 (46 ed. 1992) | Apr 20, 2018 | EXHIBIT | PETITIONER |
Trademark Manual of Examining Procedure (TMEP) | Apr 20, 2018 | EXHIBIT | PETITIONER |
Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Products | Apr 20, 2018 | EXHIBIT | PETITIONER |
Riddle et al., Anxiolytics, adrenergic agents, and naltrexone | Apr 20, 2018 | EXHIBIT | PETITIONER |
Rothenberg et al., Behavioral naltrexone therapy: an integrated treatment for opiate dependence | Apr 20, 2018 | EXHIBIT | PETITIONER |
LinkedIn profile of Steve Wright | Apr 20, 2018 | EXHIBIT | PETITIONER |
General Notices and Requirements, USP 32/NF 27 (2009) at 8 | Apr 20, 2018 | EXHIBIT | PETITIONER |
Bertil Abrahamsson and Anna-Lena Ungell, Biopharmaceutical support in formulation development | Apr 20, 2018 | EXHIBIT | PETITIONER |
B.A. Johnson, Naltrexone long-acting formulation in the treatment of alcohol dependence | Apr 20, 2018 | EXHIBIT | PETITIONER |
Food and Drug Administration, Guidance for Industry, Exposure-response relationships study design, data analysis, and regulatory applications | Apr 20, 2018 | EXHIBIT | PETITIONER |
Food and Drug Administration, Guidance for Industry, Statistical approaches to establishing bioequivalence | Apr 20, 2018 | EXHIBIT | PETITIONER |
Schenker et al., Antecedent liver disease and drug toxicity | Apr 20, 2018 | EXHIBIT | PETITIONER |
LinkedIn profile of Mike Ramstack | Apr 20, 2018 | EXHIBIT | PETITIONER |
LinkedIn profile of Richard Reuning | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Patent No. 3,332,950 | Apr 20, 2018 | EXHIBIT | PETITIONER |
CV of Dr. Park | Apr 20, 2018 | EXHIBIT | PETITIONER |
Food and Drug Administration, FDA PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEETING VIVITROL | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Securities and Exchange Commission, FORM 10-K | Apr 20, 2018 | EXHIBIT | PETITIONER |
U.S. Trademark Application Serial Number 76/271,990 | Apr 20, 2018 | EXHIBIT | PETITIONER |
Henry R. Kranzler et al., Sustained-Release Naltrexone for Alcoholism Treatment: A Preliminary Study | Apr 20, 2018 | EXHIBIT | PETITIONER |
Rubio, et al., Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment | Apr 20, 2018 | EXHIBIT | PETITIONER |
Sandra D. Comer et al., Depot naltrexone: long-lasting antagonism of the effects of heroin in humans | Apr 20, 2018 | EXHIBIT | PETITIONER |
Filing Details for Alkermes Inc. 10-K dated July 1, 2007 from the Security and Exchange Commission's EDGAR Online Filing System | Apr 20, 2018 | EXHIBIT | PETITIONER |
WayBack Machine capture of Security and Exchange Commissions Information Page regarding the Electronic Data Gathering, Analysis, and Retrieval System (EDGAR), June 6, 2002 | Apr 20, 2018 | EXHIBIT | PETITIONER |
WayBack Machine capture of Security and Exchange Commissions Regulator Overview of the Electronic Data Gathering, Analysis, and Retrieval System (EDGAR), June 6, 2002 | Apr 20, 2018 | EXHIBIT | PETITIONER |
Declaration of Kinam Park, Ph.D. | Apr 20, 2018 | EXHIBIT | PETITIONER |
Cover Letter re Exhibits | Apr 20, 2018 | PAPER | PETITIONER |
Power of Attorney | Apr 20, 2018 | PAPER | PETITIONER |
Petition for Inter Partes Review | Apr 20, 2018 | PAPER | PETITIONER |